使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good morning, and welcome to the Acadia Healthcare's second quarter 2026 earnings conference call. (Operator Instructions) Please note, this event is being recorded. I would now like to turn the conference over to Jason Plagman. Please go ahead.
早安,歡迎參加 Acadia Healthcare 2026 年第二季財報電話會議。(接線員指示) 請注意,本活動將被錄音。現在我想將會議交給 Jason Plagman。請開始。
Jason Plagman - Vice President, Investor Relations
Jason Plagman - Vice President, Investor Relations
Thank you, and good morning. Yesterday after the market closed, we issued a press release announcing our second quarter 2026 financial results. This press release can be found on the Investor Relations section of the acadiahealthcare.com website. Today, Debbie Osteen, Acadia's Chief Executive Officer; and David Duckworth, Interim Chief Financial Officer, will discuss the results.
謝謝,各位早安。昨天收盤後,我們發布新聞稿,公布 2026 年第二季財務結果。該新聞稿可於 acadiahealthcare.com 網站的投資人關係專區查閱。今天,Acadia 執行長 Debbie Osteen 與代理財務長 David Duckworth 將討論本次結果。
To the extent any non-GAAP financial measures is discussed in today's call, you will also find a reconciliation of that measure to the most directly comparable financial measure calculated according to GAAP in the press release that is posted on our website. This conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including statements, among others, regarding Acadia's expected quarterly and annual financial performance for 2026 and beyond.
若今日電話會議中討論任何非 GAAP 財務衡量指標,您也可在我們網站所發布的新聞稿中,找到該指標與依 GAAP 計算之最直接可比財務衡量指標之調節表。本電話會議可能包含《1995 年私人證券訴訟改革法》所定義的前瞻性陳述,其中包括但不限於關於 Acadia 對 2026 年及其後預期之季度與年度財務表現的陳述。
These statements may be affected by the important factors among others, set forth in Acadia's filings with the Securities and Exchange Commission and in the company's second quarter news release. And consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements.
這些陳述可能受到多項重要因素影響(其中包括)Acadia 向美國證券交易委員會提交之文件以及公司第二季新聞稿中所載之因素。因此,實際營運與結果可能與前瞻性陳述中討論的結果存在重大差異。
At this time, I would like to turn the conference call over to Debbie.
此刻,我想將電話會議交給 Debbie。
Debra Osteen - Chief Executive Officer, Director
Debra Osteen - Chief Executive Officer, Director
Good morning, and thank you for joining us. I'm pleased to be with you today to discuss Acadia's results for the second quarter of 2026. Overall, Acadia delivered solid results in the second quarter that were consistent with our expectations across our key financial and operating metrics including revenue, adjusted EBITDA, adjusted EPS and free cash flow. David and I will discuss our results in more detail.
各位早安,感謝各位加入。我很高興今天能與各位一同討論 Acadia 2026 年第二季的業績。整體而言,Acadia 在第二季交出穩健成果,且在包括營收、調整後 EBITDA、調整後 EPS 與自由現金流等關鍵財務與營運指標上,符合我們的預期。David 與我將更詳細地說明我們的結果。
As always, Acadia is guided by our mission to provide compassionate care that improves lives, inspires hope and elevates communities. Our capabilities allow us to stand as a leader in the behavioral health care industry to the important work we do. Since I returned as CEO six months ago, we have refocused on our key priorities in order to create lasting value for our patients and communities, our partners, our employees and our investors. We are building on our strong foundation with operational discipline.
一如既往,Acadia 以我們的使命為指引:提供富有同理心的照護,以改善生命、點燃希望並提升社區。我們的能力使我們能在行為健康照護產業中成為領導者,持續推動我們所從事的重要工作。自我於六個月前回任執行長以來,我們已重新聚焦於關鍵優先事項,以為病患與社區、合作夥伴、員工與投資人創造長期價值。我們正以營運紀律為基礎,延續我們堅實的根基。
As I discussed last quarter, our primary focus in 2026 continues to be on operational execution and serving patients through our existing facilities and our new locations. I'm pleased to say that we have made significant advances on these priorities in the first half of the year, and we are confident in our ability to deliver further progress in the coming quarters.
如我在上季所述,我們 2026 年的主要重點仍在於營運執行,並透過既有設施與新據點服務病患。我很高興地表示,我們在上半年已在這些優先事項上取得顯著進展,且我們對於在未來幾季持續推進更有信心。
Looking at our second quarter results, a few notable highlights include the following: we delivered revenue that was above the high end of our guidance range as well as adjusted EBITDA and adjusted EPS that were near the high end of our guidance. We generated $124 million of free cash flow and reduced our debt by $113 million. We are taking a disciplined approach to capital deployment, including CapEx, and we expect to generate additional free cash flow in the second half of the year. During the quarter, we opened two new acute facilities on schedule. A 144-bed JV facility with Orlando Health in Florida and a 96-bed JV facility with Methodist Jennie Edmundson in Iowa.
回顧第二季結果,幾項值得注意的重點如下:我們的營收高於指引區間上緣,而調整後 EBITDA 與調整後 EPS 亦接近指引上緣。我們創造了 1.24 億美元的自由現金流,並將債務降低 1.13 億美元。我們對資本配置(包括資本支出 CapEx)採取嚴謹作法,並預期在下半年產生更多自由現金流。本季我們如期開設兩家新的急性照護機構。分別為佛羅里達州與 Orlando Health 合作的 144 床合資(JV)機構,以及愛荷華州與 Methodist Jennie Edmundson 合作的 96 床合資(JV)機構。
For the second quarter, our total revenue was flat compared with the prior year period. After normalizing for the impact of the timing of supplemental payments related to prior periods in Florida and Tennessee, our total revenue growth would have been 2.8% on a year-over-year basis and 3.2% on same-facility revenue growth.
第二季總營收與去年同期相比持平。若將佛羅里達州與田納西州與前期相關之補充付款(supplemental payments)時點影響予以常態化調整,我們的總營收年增率將為 2.8%,同設施營收年增率將為 3.2%。
In our acute business, we saw continued progress in ramping occupancy and revenue at our new facilities that have opened over the last few years. And our growth in same-facility volumes was consistent with our expectations. Our Specialty business delivered solid performance in the second quarter, including a $5 million sequential increase in revenue. The team also made progress in mitigating some of the impact on our Pennsylvania facilities related to changes in the New York Medicaid program that we discussed in prior quarters. Our RTC business delivered strong revenue growth in the second quarter, driven by volume growth and capacity expansions that were completed last year.
在急性照護業務方面,我們看到近幾年新開設機構的入住率與營收持續爬坡並取得進展。同設施量(volume)的成長符合我們的預期。我們的專科(Specialty)業務在第二季表現穩健,營收較前一季增加 500 萬美元。團隊也在降低我們先前討論過、因紐約州 Medicaid 計畫變更而對賓夕法尼亞州設施造成的部分影響方面取得進展。我們的 RTC 業務在第二季實現強勁營收成長,主要由量的成長與去年完成的產能擴增所帶動。
In our CTC service line, revenue was flat on a year-over-year basis. Our CTC clinics provide important services that are highly valued by patients, families and payers, and we opened two new CTC clinics during the second quarter.
在 CTC 服務線方面,營收年增持平。我們的 CTC 診所提供重要服務,深受病患、家庭與支付方重視,而我們在第二季新開設兩家 CTC 診所。
Our adjusted EBITDA for the second quarter was $149.2 million. Adjusted EBITDA includes two items that were not included in our guidance. A benefit related to the Florida supplemental payment program and an expense related to an increase in our professional and general liability reserves for prior years. The combined impact of these two items was a $2.5 million reduction to adjusted EBITDA in the second quarter. David will provide additional details.
第二季調整後 EBITDA 為 1.492 億美元。調整後 EBITDA 包含兩項未納入我們指引的項目。一項與佛羅里達州補充付款計畫相關的利益,以及一項與提高前年度專業責任與一般責任準備金相關的費用。這兩項合計對第二季調整後 EBITDA 的影響為減少 250 萬美元。David 將提供更多細節。
Switching to our key operational priorities. We continue to focus on delivering more value from our increased bed capacity and the new facilities that we've opened over the last few years. During the second quarter, we made further progress with that group, including revenue and facility level EBITDA results for those 2023 to 2026 cohorts that were ahead of our expectations.
接著談我們的關鍵營運優先事項。我們持續聚焦於從新增床位產能以及過去幾年開設的新機構中創造更多價值。第二季我們在該群組上進一步取得進展,包括 2023 至 2026 年批次(cohorts)之營收與機構層級 EBITDA 結果均優於我們的預期。
I am pleased with the progress we've made in these facilities. And I want to highlight a few contributing factors that have enabled this success. First, our team has been operating with a heightened sense of urgency and focus, which has allowed us to accelerate time lines across multiple critically important milestones for new facilities, including licensing, accreditation and payer contracting. Second, we've been emphasizing expense discipline alongside the occupancy ramp through a focus on execution, ensuring our facilities have the resources necessary to support patient care and operational needs. Third, we're maintaining strong referral partnerships in the markets we serve.
我對這些機構所取得的進展感到滿意。我也想強調幾項促成此成功的因素。第一,我們的團隊以更強的急迫感與專注度運作,使我們得以加速新機構多項至關重要里程碑的時程,包括執照申請、認證(accreditation)以及與支付方簽約。第二,在入住率爬坡的同時,我們也強調費用紀律並聚焦執行,確保各機構具備支持病患照護與營運需求所需的資源。第三,我們在所服務市場中維持強健的轉介合作夥伴關係。
We've increased our focus on consistent communication with our JV partners to better align around shared growth objectives, patient access and ensuring that patients are receiving the right care at the right level and in the right setting.
我們也加強與合資(JV)夥伴之間的一致性溝通,以更好地就共同成長目標、病患可近性,以及確保病患在正確的照護層級與正確的場域接受適切照護達成一致。
The organization is now operating with a clear set of priorities and has the right resources in place. And the combination of ramping volumes and disciplined expense control has allowed us to outperform our start-up targets for two quarters in a row. An increasing number of our new facilities are beginning to contribute positive adjusted EBITDA. We remain confident in this group, delivering on the $200 million of incremental adjusted EBITDA relative to 2025 that we've discussed previously.
目前組織已依一套清晰的優先事項運作,並已配置到位適當資源。而量的爬坡與嚴謹的費用控管相結合,使我們連續兩季優於新設機構的啟動目標。我們愈來愈多的新機構開始貢獻正向的調整後 EBITDA。我們對此群組仍具信心,將實現我們先前討論過、相較 2025 年增加 2 億美元調整後 EBITDA 的目標。
We also continue to strengthen our leadership team at both the corporate level and at our facilities as we focus on having the right leaders in place to support our facilities. We are seeing increasing benefits from our decision to refine the structure of our acute service line. And we are confident that we will continue to see clinical excellence and consistent value over the coming quarters.
我們也持續在公司層級與各院區強化領導團隊,並聚焦於配置合適的領導者,以支援各院區營運。我們正看到先前決定優化急性照護服務線架構所帶來的效益持續增加。我們也有信心在未來幾個季度持續看到臨床卓越表現與一致的價值。
We are also advancing in our initiatives to deliver quality care for the patients that we serve. For example, we are expanding our measurement-based care initiative to additional acute facilities as well as through our specialty and CTC service lines. We are leveraging evidence-based practices to guide clinical decision-making and improved treatment outcomes. It allows clinicians to use real-time data to identify changes in symptoms, adjust treatment plans and help patients remain engaged in their own care.
我們也在推進各項計畫,以為我們服務的病患提供高品質照護。例如,我們正將以量測為基礎的照護(measurement-based care)計畫擴展至更多急性照護院區,並透過我們的專科與 CTC 服務線推動。我們運用實證為本的作法來引導臨床決策並改善治療結果。這讓臨床人員能使用即時數據辨識症狀變化、調整治療計畫,並協助病患持續投入自身照護。
As I reviewed earlier, we are also pleased to share that we successfully opened two new acute facilities in June in partnership with Premier Health Systems. In total, we've added over 300 beds in the first half of the year, and we remain on track to add 500 to 600 beds in 2026 including our planned opening in the third quarter of a de novo acute facility near Jacksonville, Florida.
如我先前所述,我們也很高興分享,我們已於 6 月與 Premier Health Systems 合作,成功開設兩家新的急性照護院區。今年上半年合計新增超過 300 張病床;我們仍按計畫在 2026 年新增 500 至 600 張病床,其中包括我們預計於第三季在佛羅里達州傑克遜維爾附近新設(de novo)的急性照護院區開幕。
As we look ahead, we see the demand for our services remain strong, and we are well positioned with added capacity to meet this demand. Above all, we remain committed to our mission and to providing clinical excellence for patients and the communities we serve.
展望未來,我們看到對我們服務的需求仍然強勁,而我們也已透過新增產能做好準備以滿足這項需求。最重要的是,我們仍致力於我們的使命,並為病患與我們所服務的社區提供臨床卓越的照護。
With that, I will turn it over to David to review the financial details.
接下來,我將交給 David 來說明財務細節。
David Duckworth - Interim Chief Financial Officer
David Duckworth - Interim Chief Financial Officer
Thanks, Debbie, and good morning, everyone. I'm glad to be back at Acadia Healthcare and collaborating with the team as we execute on our mission and build upon our leadership position in the behavioral health care industry.
謝謝你,Debbie,各位早安。我很高興回到 Acadia Healthcare,並與團隊合作,在我們落實使命的同時,持續鞏固我們在行為健康照護產業的領導地位。
Looking at our second quarter results, we reported revenue of $866 million, which was flat compared to the second quarter of last year. As previously discussed, the second quarter of 2025 included $48.7 million of revenue from the Tennessee supplemental payment program that related to prior periods. Our second quarter results this year include $22.3 million of revenue from the Florida supplemental payment program related to the 2025 program year. After normalizing for these two items, our total revenue growth would have been 2.8%.
就第二季業績而言,我們的營收為 8.66 億美元,與去年第二季相比持平。如先前所討論,2025 年第二季包含田納西州補充支付計畫中與先前期間相關的 4,870 萬美元營收。而今年第二季的結果包含佛羅里達州補充支付計畫(對應 2025 計畫年度)的 2,230 萬美元營收。若將這兩項因素標準化(剔除其影響),我們的總營收成長本應為 2.8%。
Same-facility revenue in the second quarter was flat on a year-over-year basis with a 0.8% increase in patient days, offset by a 0.8% decrease in revenue per patient day. After normalizing for the impact of the Florida and Tennessee supplemental payments related to prior periods, our same-facility revenue growth would have been 3.2%. Our same-facility revenue growth rate was further impacted by approximately 1% from the changes in the New York Medicaid program on our Pennsylvania facilities.
第二季同院(same-facility)營收以年對年來看持平:病患日數增加 0.8%,但被每病患日營收下降 0.8%所抵銷。若將佛羅里達州與田納西州、且與先前期間相關的補充支付影響標準化後,我們的同院營收成長本應為 3.2%。此外,我們的同院營收成長率亦受到約 1% 的影響,原因是紐約州 Medicaid 計畫變更對我們賓夕法尼亞州院區造成的影響。
Revenue in our Acute business was $495 million in the second quarter, which was flat on a year-over-year basis, but reflects 6% growth after normalizing for the supplemental payments related to prior periods. We delivered strong volume and admissions growth in the second quarter from both existing acute facilities and our new JV and de novo facilities.
第二季我們急性照護(Acute)業務營收為 4.95 億美元,年對年持平;但若將與先前期間相關的補充支付影響標準化後,則反映 6% 的成長。第二季我們在既有急性照護院區,以及新成立的合資(JV)與新設(de novo)院區,均帶來強勁的量能與入院成長。
Specialty revenue in the second quarter was $134 million and increased 4% sequentially as compared with the first quarter. The second quarter included a full quarter of impact on our specialty business from the New York Medicaid decision that was implemented at the beginning of the year. Our team continues to work to build upon and expand our referral sources within Pennsylvania and in additional states.
第二季專科(Specialty)營收為 1.34 億美元,較第一季季增 4%。第二季已完整反映年初實施的紐約州 Medicaid 決策對我們專科業務的影響。我們的團隊持續努力,在賓夕法尼亞州及其他州強化並擴大轉介來源。
In our RTC service line, revenue in the second quarter was $97 million, and increased 12% year-over-year, driven by solid volume growth as well as growth in revenue per day. In our CTC business, second quarter revenue was $141 million. Demand for CTC services remains steady, and our team is focused on meeting the needs of current and potential patients.
在我們的 RTC 服務線方面,第二季營收為 9,700 萬美元,年對年成長 12%,主要由穩健的量能成長以及每日營收成長所帶動。在我們的 CTC 業務方面,第二季營收為 1.41 億美元。CTC 服務需求仍維持穩定,我們的團隊專注於滿足現有與潛在病患的需求。
Moving down the income statement. Adjusted EBITDA for the second quarter was $149.2 million. Adjusted EBITDA includes two significant items that were not included in our guidance, a $26.1 million benefit from Florida supplemental payments related to the 2025 program year, which is offset by a $28.6 million actuarial adjustment to increase the company's professional and general liability or PLGL reserves. The total impact of these two items was a negative $2.5 million impact on second quarter adjusted EBITDA relative to our guidance provided in April.
接著往下看損益表。第二季調整後 EBITDA 為 1.492 億美元。調整後 EBITDA 包含兩項未納入我們財測指引的重要項目:一是佛羅里達州補充支付(與 2025 計畫年度相關)帶來 2,610 萬美元的利益;二是精算調整使公司專業與一般責任(professional and general liability,PLGL)準備金增加 2,860 萬美元,兩者相互抵銷。這兩項合計對第二季調整後 EBITDA 相較於我們 4 月提供的指引,造成負面影響 250 萬美元。
With respect to the PLGL adjustment, we made a proactive decision going into 2026 to conduct midyear actuarial reviews in addition to our traditional fourth quarter review. This quarter's PLGL adjustment is primarily driven by our progress in moving towards settlement related to certain prior year cases from the 2025 policy year. While reserves for the current year are trending in line with our expectations, the resolution of these prior year matters was incorporated into the midyear actuarial reserve estimates and were the primary driver of the adjustment.
就 PLGL 調整而言,我們為了在邁入 2026 年前更為審慎,主動決定除傳統的第四季審查外,另於年中進行精算審查。本季的 PLGL 調整主要來自我們在推進與 2025 保單年度某些前期年度案件相關的和解進程。雖然本年度的準備金趨勢符合我們預期,但這些前期年度事項的解決情況已納入年中精算準備金估計,並成為本次調整的主要驅動因素。
On a same-facility basis, adjusted EBITDA was $200.9 million in the second quarter. Our focus on operational discipline helped drive strong cost efficiencies at both the corporate level and at our facilities in the second quarter. Our corporate overhead cost declined by approximately $3 million compared with the first quarter and were flat on a year-over-year basis.
以同院基礎計算,第二季調整後 EBITDA 為 2.009 億美元。我們對營運紀律的專注,推動第二季在公司層級與各院區均實現顯著的成本效率。我們的公司管理費用較第一季下降約 300 萬美元,且年對年持平。
Outside of the same-facility group, our losses from start-up facilities were $12 million in the second quarter, which was better than our expectation. Start-up losses in the second quarter included a ramp-up in preopening expenses as we prepared for the two new facility openings that Debbie mentioned. For closed facilities, we had $1 million in operating losses during the second quarter.
在同院群組之外,我們第二季新設/起步院區(start-up facilities)的虧損為 1,200 萬美元,優於我們的預期。第二季的起步虧損包含開幕前費用的加速投入,因我們正為 Debbie 提到的兩家新院區開幕做準備。至於已關閉院區,第二季我們有 100 萬美元的營運虧損。
Moving to the balance sheet. We remain in a solid financial position. As of June 30, 2026, we had $171 million in cash and cash equivalents. Operating cash flow in the second quarter was $162 million, and capital expenditures were $39 million, resulting in free cash flow of $124 million. We repaid $113 million on our debt during the second quarter, and our net leverage ratio at the end of the quarter stood at approximately 4.1 times adjusted EBITDA. From a revenue cycle perspective, our bad debt and denials in the second quarter were stable, and our days sales outstanding or DSOs declined compared to the first quarter.
接著看資產負債表。我們仍維持穩健的財務狀況。截至 2026 年 6 月 30 日,我們持有 1.71 億美元的現金及約當現金。第二季營運現金流為 1.62 億美元,資本支出為 3,900 萬美元,因此自由現金流為 1.24 億美元。第二季我們償還 1.13 億美元債務,季末淨槓桿比率約為調整後 EBITDA 的 4.1 倍。就營收循環而言,我們第二季的壞帳與拒付(denials)維持穩定,而應收帳款週轉天數(DSO)較第一季下降。
With respect to capital expenditures, following a review of our ongoing and planned capital projects, we have revised our full year forecast for CapEx to a range of $235 million to $255 million, which includes a range of $120 million to $140 million for the second half of the year. This updated expectation reflects our focus on free cash flow and our disciplined approach to capital deployment as well as the timing of our capital projects. We expect positive free cash flow in the second half of 2026.
就資本支出而言,在審視我們正在進行及規劃中的資本專案後,我們已將全年資本支出(CapEx)預測修訂為2.35億至2.55億美元的區間,其中包含下半年1.20億至1.40億美元的區間。此一更新後的預期反映了我們對自由現金流的重視、對資本配置的紀律性作法,以及資本專案的時程安排。我們預期2026年下半年將產生正向自由現金流。
Turning to our guidance. We are updating our guidance ranges based on progress made this year and our updated full year guidance now reflects revenue in a range of $3.4 billion to $3.45 billion, adjusted EBITDA in a range of $590 million to $615 million, adjusted EPS in a range of $1.45 to $1.60 and operating cash flow in a range of $350 million to $400 million.
接著談我們的財測指引。我們基於今年迄今的進展更新指引區間;更新後的全年指引反映:營收介於34億至34.5億美元,調整後EBITDA介於5.90億至6.15億美元,調整後EPS介於1.45至1.60美元,營運現金流介於3.50億至4.00億美元。
Our team continues to monitor supplemental payment programs that we believe could be approved in 2026. We have not fully reflected expanded programs in our guidance at this time beyond a $5 million historical baseline amount for Florida that is included in our Q3 expectations. We estimate that programs in Florida and Ohio currently under regulatory review for the 2026 program year could add more than $20 million in incremental EBITDA.
我們的團隊持續關注我們認為可能在2026年獲核准的補充支付計畫。目前我們尚未在指引中充分反映擴大後的計畫,僅納入佛羅里達州歷史基準金額500萬美元(已包含在我們對第三季的預期中)。我們估計,目前正就2026計畫年度接受監管審查的佛羅里達州與俄亥俄州計畫,可能帶來超過2,000萬美元的增量EBITDA。
I will now turn the call back over to Debbie.
我現在把電話交回給Debbie。
Debra Osteen - Chief Executive Officer, Director
Debra Osteen - Chief Executive Officer, Director
We've made significant progress on our key priorities in the first half of the year, and we expect to deliver consistent operational performance in the coming quarters. Acadia is fortunate to have an experienced and dedicated team who work every day to improve the lives of the patients we serve. We have an important mission to provide safe, quality care and we share a clear purpose, meeting a critical need and making a difference in the communities we serve.
我們在上半年於關鍵優先事項上取得顯著進展,並預期在接下來幾季交出一致的營運表現。Acadia很幸運擁有一支經驗豐富且投入的團隊,每天致力於改善我們所服務病患的生活。我們肩負提供安全且高品質照護的重要使命,也共享清晰的目標:滿足關鍵需求,並在我們服務的社區中帶來改變。
With that, we will now turn it over to the operator for questions.
接下來,我們將交由接線員進行提問。
Operator
Operator
(Operator Instructions)
(接線員指示)
Brian Tanquilut, Jefferies.
Brian Tanquilut,Jefferies。
Brian Tanquilut - Equity Analyst
Brian Tanquilut - Equity Analyst
Congrats on solid quarter. Debbie, maybe first, as I think about your comments on the continued confidence in the $200 million of brands in the beds that were opened from '23 through '26. Just thinking, are there any measures or qualitative comments you can share with us in terms of the progress that you're already seeing there other than the 2.5% or so growth rate that we saw in those net cohorts. So just curious, anything you can share with us in terms of achievability of that path and the progress you're making there?
恭喜本季表現穩健。Debbie,首先,關於你提到對於自2023年至2026年開設床位所帶來的2億美元品牌(增量)仍持續有信心。我在想,除了我們在那些淨同批(net cohorts)看到約2.5%的成長率之外,你是否能分享任何衡量指標或質性的評論,說明你們目前已看到的進展?所以我很好奇,你能否分享這條路徑的可達成性,以及你們在這方面的推進進度?
Debra Osteen - Chief Executive Officer, Director
Debra Osteen - Chief Executive Officer, Director
Thank you, Brian. I mean, we have confidence in delivering on the $200 million of the incremental adjusted EBITDA. It's been a significant focus for the team. I think we've made further progress during the second quarter with really revenue volume, facility level EBITDA. They were ahead of our expectations for each cohort.
謝謝你,Brian。我的意思是,我們有信心達成2億美元的增量調整後EBITDA。這一直是團隊的重點工作。我認為我們在第二季於營收量、院所層級EBITDA方面都取得了進一步進展。各個同批的表現都超出我們的預期。
We expect to deliver additional progress and visibility over the second half of 2026. And as the facilities continue to ramp each step gives us more confidence and visibility to the $200 million that we feel very, very confident about.
我們預期在2026年下半年能帶來更多進展與能見度。隨著各院所持續爬坡,每一步都讓我們對2億美元目標更有信心、能見度也更高;對此我們非常、非常有信心。
I'll give an example of the cohort is one, which is Cochela Valley. We have made very, very good progress there, and it was one of our 2024 de novo facilities. It's now above 90% occupancy. And we're actually planning and looking at building additional beds, which we think we can do with the space that may already be there. We want to meet the demand in the market.
我舉第一批(cohort one)的例子,也就是Cochela Valley。我們在那裡取得非常、非常好的進展;那是我們在2024年新設(de novo)的院所之一。目前入住率已超過90%。而且我們實際上正在規劃並評估增建更多床位;我們認為可利用可能已存在的空間來完成。我們希望滿足市場需求。
And so that's one facility that I can point out. And we have others that are now positive EBITDA, but it's really a result of all of what the team has done to focus on new dashboards, strategic plans to build occupancy and really to be ready to meet the needs of our partners in the community.
所以這是一家我可以指出的院所。另外也有其他院所目前已轉為EBITDA為正,但這確實是團隊所做一切努力的成果:聚焦於新的儀表板、提升入住率的策略計畫,並真正做好準備以滿足我們在社區中的合作夥伴需求。
Brian Tanquilut - Equity Analyst
Brian Tanquilut - Equity Analyst
I appreciate that. And then maybe, David, just real quickly, obviously, you raised the EBITDA guidance, but the free cash flow or the operating cash flow guidance is pretty notable. Just curious what is driving that delta? And then what are the levers that you pull to get that CapEx spend targets down?
了解,謝謝。接著也許問David,很快地:很明顯你們上調了EBITDA指引,但自由現金流或營運現金流指引也相當引人注目。我想了解是什麼因素造成這個差異(delta)?另外,你們透過哪些槓桿把資本支出目標降下來?
David Duckworth - Interim Chief Financial Officer
David Duckworth - Interim Chief Financial Officer
Yes. Thank you, Brian. We were pleased with the free cash flow performance during the second quarter, and expect that to continue into the back half of the year. And it is attributable to strong performance in the core business and strong execution on many of our new facilities in addition to just some EBITDA visibility and confidence in the full year number that we have after being through the first part of the year, moving into the second half of the year. We're also seeing positive trends in our working capital and would highlight that AR days decline relative to where they were, not only in the first quarter, but the forecast that we had going into the year with respect to AR days.
是的。謝謝你,Brian。我們對第二季的自由現金流表現感到滿意,並預期這樣的表現會延續到下半年。這主要歸因於核心業務的強勁表現,以及我們在多家新院所的強力執行;此外,隨著我們走過上半年、進入下半年,我們對全年數字的EBITDA能見度與信心也提升。我們也看到營運資金的正向趨勢,特別要強調應收帳款天數(AR days)相較於先前水準下降,不僅相較第一季,也優於我們年初對AR days的預測。
We are pleased to be at 49% at the end of the second quarter. And that is a key contributor to not only our second quarter performance on operating cash flows, but our outlook in the back half of the year. There are a few other items that we would point to just related to other working capital management initiatives that we have as a company. In addition to cash interest and a few other items being lower than we had forecasted with our ability to pay down some debt during the quarter. So pleased with that performance.
我們很高興在第二季末達到49%。這是我們第二季營運現金流表現,以及對下半年展望的重要貢獻因素。另外還有幾項我們會指出的因素,主要與公司其他營運資金管理措施有關。此外,現金利息與其他幾個項目也低於我們原先預測,因為我們在本季有能力償還部分債務。因此對這樣的表現感到滿意。
From a CapEx perspective, we also went through all of our projects in detail our expansion and other projects in detail. Some of the lower number during the second quarter does just reflect timing. And you can see in our second half outlook, there is some increase relative to where we were in the second quarter. But we have a disciplined approach to not only managing our existing projects, but managing any additional expansion or maintenance projects moving forward, and are pleased to just see the free cash flow performance of the business really across both earnings items, working capital and just a more disciplined approach to capital expenditures.
就資本支出而言,我們也對所有專案進行了詳細檢視,包括擴建與其他專案。第二季數字較低,部分只是時點因素所致。而你也可以在我們對下半年的展望中看到,相較第二季會有一些增加。但我們採取有紀律的方法,不僅管理既有專案,也管理未來任何額外的擴建或維護專案;我們也很高興看到公司自由現金流表現的改善,這反映在獲利項目、營運資金,以及對資本支出更有紀律的作法上。
Operator
Operator
AJ Rice, UBS.
AJ Rice,UBS。
AJ Rice - Analyst
AJ Rice - Analyst
Debbie, when you came on six, seven months ago, the company over the last year or two had faced the number of challenges, some related to managed care contract, some related to litigation. I think there was also some uncertainty around the pacing of development JVs and so forth and how the returns on those would look. Maybe just if you could comment on where you've made progress, where there's still opportunities to be added maybe in those areas or any other that you'd highlight?
Debbie,你在六、七個月前加入時,公司在過去一兩年面臨不少挑戰,有些與管理式醫療合約有關,有些與訴訟有關。我想在開發合資(JV)的推進節奏,以及這些投資報酬看起來如何方面,也存在一些不確定性。也許你可以談談你們在哪些方面已取得進展、哪些方面仍有可加強的機會(也許就在上述領域或其他你會特別點出的地方)?
Debra Osteen - Chief Executive Officer, Director
Debra Osteen - Chief Executive Officer, Director
Sure, A.J. I mean we really have the back to basics, and you mentioned some of the challenges that the company faced. But I think just building a strong experienced operations team has just made a big difference to our focus and our execution. And as I think about what we've been able to accomplish in the first two quarters, we are seeing those facilities in the cohorts, which I talked about just a minute ago, ramp actually exceeding our expectations on that.
當然,A.J.。我的意思是,我們確實回歸基本面,而你也提到公司所面臨的一些挑戰。但我認為,建立一支強而有經驗的營運團隊,對我們的專注度與執行力帶來了很大的差異。而當我回顧我們在前兩個季度所能達成的成果時,我們看到我剛才提到的那些分組(cohorts)中的設施,其爬坡(ramp)表現實際上超出我們的預期。
I think that we continue to have positive strong relationships with our referral sources. They -- we are now able to show them outcomes, which has been a very keen focus for not just the clinical team, but the operational team in the field to be able to demonstrate what we do. But we really -- we're focused on problem solving. So as things come up, and we see something that is not going as we expected. And the team is really doing a good job of saying, what can we do to change this?
我認為我們持續與轉介來源維持正向且穩固的關係。他們——我們現在能夠向他們展示成果(outcomes),這一直是重點關注方向,不僅是臨床團隊,現場的營運團隊也同樣聚焦於能夠證明我們所做的事情。但我們確實——我們專注於解決問題。因此當事情發生、我們看到某些狀況沒有如預期進行時,團隊真的做得很好,會去思考:我們能做些什麼來改變這個狀況?
What actions do we need to take? We developed additional dashboards that we can look at to monitor our progress, not just on the cohorts, the 2023 to 2026 that on our same facility metrics as well as looking at expense management that has -- the team has done a great job there of just let's make sure we're matching our staffing to the needs of our patients.
我們需要採取哪些行動?我們開發了額外的儀表板(dashboards),用來監控我們的進展,不僅針對分組(cohorts)——也就是2023到2026——同時也看我們同一設施(same facility)的指標,並且檢視費用管理;在這方面團隊做得非常好,就是確保我們的人力配置能與病患需求相匹配。
So all of that has come together and there's a real momentum that I think we have. So as we look for the second half of the year, I think we're going to continue to see the progress. And I believe that as we start to execute as we're doing now, that that's going to be sustainable. And so I'm very encouraged, and I know the team, they worked very well together, and they're also working very hard to make sure that we improve what we can control and that we are able to see the value of the investments that we've made.
所以這一切都整合起來了,我認為我們確實有一股動能。因此當我們展望下半年時,我認為我們會持續看到進展。我也相信,隨著我們像現在這樣開始落實執行,這將會是可持續的。所以我非常受到鼓舞;我也知道團隊彼此合作得很好,同時也非常努力,確保我們改善那些我們能控制的事情,並且能看到我們已投入的投資所帶來的價值。
AJ Rice - Analyst
AJ Rice - Analyst
Okay. And maybe just labor. I know in this segment, that's sometimes a gating factor on your ability to get growth, the ability to get people at reasonable rates. What are you seeing in labor? What is the wage rates turnover? Any updated thoughts on that?
好的。另外也許談一下人力。我知道在這個領域,人力有時候會成為你能否成長的限制因素,包含能否以合理的成本找到人。你們在人力方面看到什麼情況?薪資水準與離職率如何?對此有沒有任何更新的看法?
David Duckworth - Interim Chief Financial Officer
David Duckworth - Interim Chief Financial Officer
Yes, A.J., we are continuing to see a stable and positive labor environment and have seen for several quarters just a strong recruiting ability to recruit as well as just a retention of our existing employees. And importantly, as we bring on new facilities and new beds, we have had success bringing on new teams and are just very excited to bring on new leadership teams at our new facilities and build staff and have been able to do that at our new facilities.
是的,A.J.,我們持續看到穩定且正向的人力環境,而且已經連續好幾個季度都看到強勁的招募能力——不僅招得到人,也能留住現有員工。而且很重要的是,當我們新增設施與新增床位時,我們在組建新團隊方面也很成功;我們對於在新設施引進新的領導團隊、建立人員編制感到非常振奮,而且我們確實也能在新設施做到這點。
And at the same time, just we mentioned operating discipline, just making sure across the company, corporate and at our facilities, we have the right discipline and focus on staffing just as we ramp up our census in certain facilities. And the team has done a great job just managing and having the right resources for our facilities.
同時,正如我們提到的營運紀律,就是要確保在全公司層面——包含總部與各設施——我們在用人方面具備正確的紀律與聚焦,尤其是在某些設施住院人數(census)爬升的過程中。團隊在管理方面做得非常好,能為各設施配置適當的資源。
From a wage perspective, it has been trending in the 3% or so level. It does depend on just the role in the geographic market and other factors. But overall, for the company, we've seen a stable year-over-year wage cost growth.
從薪資角度來看,趨勢大約在3%左右。這確實會取決於職務類型、地理市場以及其他因素。但整體而言,就公司層面來看,我們看到薪資成本年增率維持穩定。
Debra Osteen - Chief Executive Officer, Director
Debra Osteen - Chief Executive Officer, Director
A.J., I'll just add. With our JVs, one of the advantages of our partnership with them have had units and actually hospitals. So as we open and we prepared for all of the processes that we go through, we very often can bring those staff to the new facility, and that's been a real advantage of just having those partnerships.
A.J.,我再補充一下。就我們的合資企業(JVs)而言,與他們合作的一個優勢是他們本來就有單位,甚至有醫院。因此當我們開設新設施並為我們所需的各項流程做準備時,我們往往可以把那些員工調派到新設施,這一直是擁有這些合作夥伴關係的一大優勢。
Operator
Operator
Matthew Gillmor, KeyBanc.
KeyBanc 的 Matthew Gillmor。
Matthew Gillmor - Equity Analyst
Matthew Gillmor - Equity Analyst
So I wanted to ask about bad debt and payer denials. I think the year-over-year impact for bad debt with $7 million, which is a little bit better than last quarter. Can you just update us on the trends you're seeing and some of the progress that Larry has made as you come back to the team and try to tackle it?
我想問一下壞帳(bad debt)與付款方拒付(payer denials)。我認為壞帳的年對年影響是700萬美元,比上一季稍微好一些。你能否更新一下你們看到的趨勢,以及 Larry 回到團隊、著手處理這件事後所取得的一些進展?
David Duckworth - Interim Chief Financial Officer
David Duckworth - Interim Chief Financial Officer
Yes. We are encouraged to see some progress in our revenue cycle initiatives, which have been a focus in the first half of the year. And the team is doing just a good job just assisting where we do have isolated issues in certain markets and facilities related to either bad debts, denials, AR, collection, et cetera. The team is doing a nice job just making progress there.
可以。我們很受鼓舞地看到,在今年上半年重點推動的營收循環(revenue cycle)措施上出現了一些進展。而團隊在協助處理某些市場與設施中零星出現的問題方面做得很好,這些問題可能與壞帳、拒付、應收帳款(AR)、收款等相關。團隊在那方面確實取得了不錯的進展。
And we were encouraged in the second quarter to see stability in our bad debts and denials as we look at that sequentially versus Q1. We did see a stable number sequentially compared to the first quarter. And on a year-over-year basis, you mentioned the -- just the improvement on a year-over-year headwind basis from $9 million in the first quarter to a $7 million year-over-year headwind in the second quarter. And that improves as we go through the second half of the year because the second quarter -- or the second half of 2025 is where we saw a step-up in overall bad debt and denials.
而且我們在第二季也很受鼓舞,看到壞帳與拒付在序列比較上相對第一季呈現穩定。與第一季相比,我們序列上看到的數字是穩定的。而在年對年方面,你提到——年對年的不利影響(headwind)有所改善,從第一季的900萬美元降到第二季年對年不利影響700萬美元。隨著我們進入下半年,這個情況會進一步改善,因為2025年第二季——或是2025年下半年——是我們看到整體壞帳與拒付出現一個台階式上升(step-up)的時點。
And we continue to have just a three-pronged approach to improving revenue cycle performance. We mentioned the team, the revenue cycle leaders, the specialists that we have are doing a nice job just strengthening our processes, leveraging technology. Secondly, just the tools that we have to proactively intervene and assist with specific issues that we have at the payer and local level. And in select cases, the appeals and the process for appeal is important to just the way that we respond the way we learn from one market and apply that to other markets. And documentation of the care we provide and how we can just control what we can control to drive improvement going forward. But we've seen just good progress in the second half of the year with more opportunity as we look ahead into the second half of the year.
我們也持續採取三管齊下的方法來改善營收循環表現。我們提到的團隊——營收循環的主管與專家——在強化流程、運用科技方面做得很好。第二,是我們用來主動介入的工具,協助處理在付款方層級與地方層級出現的特定問題。第三,在部分案例中,上訴(appeals)以及上訴流程很重要,這關係到我們如何回應、如何從某個市場學習並套用到其他市場。以及我們所提供照護的文件化(documentation),並且聚焦於控制我們能控制的事情,以推動未來的改善。不過我們在今年下半年已經看到不錯的進展,而且展望下半年仍有更多機會。
Matthew Gillmor - Equity Analyst
Matthew Gillmor - Equity Analyst
Okay. And I was hoping to get an update on the de novo pipeline. I think you mentioned you had some other opening schedule for the third quarter. Can you just remind us what the pace is over the next few quarters? And if you had any comments on the trajectory of the startup losses and cash flow, even as you look out to '27, if you're able to comment on that, that would be great.
好的。我也希望了解一下新設(de novo)管線的最新情況。我記得你提到第三季還有一些其他的開設時程。你能否提醒我們接下來幾個季度的開設節奏大概是怎樣?另外,即使展望到2027年,如果你方便評論的話,對於新設啟動虧損(startup losses)與現金流的走勢,你有沒有任何看法?那會很有幫助。
David Duckworth - Interim Chief Financial Officer
David Duckworth - Interim Chief Financial Officer
Yes. We did mention we have one other de novo facility to bring online and that's our facility near Jacksonville, Florida, have confidence just having made so much progress in the first part of the year around new facilities and expansion projects at other facilities have just high level of visibility at this point in the year as to the 500 to 600 beds that we're adding in total for the year.
是的。我們確實提到還有另一個全新設立(de novo)的設施將投入營運,也就是我們位於佛羅里達州傑克遜維爾附近的設施;鑑於我們在今年前半段於新設施與其他設施擴建專案上已取得大量進展,我們對於今年合計新增的500到600張床位,在此時點具有高度可視性與信心。
Beyond that de novo facility, we believe the opportunity that we have as a company is the capacity that we've added over the last several years. And so we do not have, at this point, another de novo or JV project that begins in the fourth quarter or in early 2027, just based on the current pipeline. Of course, we continue to look at attractive opportunities. Some focus there just on existing facilities and not as much joint ventures and de novos, but we do continue to look at those opportunities as well. But the bed additions for the year is a strong number with high visibility and a lot of that having already happened in the first part of the year or are getting close to happening in the third quarter.
除了那個全新設立的設施之外,我們認為公司所擁有的機會在於過去幾年所增加的產能。因此,基於目前的專案管線,我們在此時點並沒有另一個將於第四季或2027年初啟動的全新設立或合資(JV)專案。當然,我們仍持續尋找具吸引力的機會。目前的重點較偏向既有設施,而不是那麼著重於合資與全新設立,但我們也仍會持續評估那些機會。不過,今年的床位新增是一個數字強勁且可視性很高的成果,其中很大一部分已在今年前半段完成,或正接近在第三季發生。
With respect to the start-up losses, we have had two quarters in a row where our losses for the facilities opening in the last 12 months has been around $12 million. Those facilities are doing a great job in the early stages of opening and are ahead of our expectations. And we revised our full year expectation there slightly and would guide everyone towards a little bit of a step-up in that $12 million as we think about the third quarter, just given two new facilities at the end of the second quarter as well as one more facility opening in the third quarter.
就開辦損失(start-up losses)而言,我們已連續兩個季度,新開設且在過去12個月內開業的設施所產生的損失約為1,200萬美元。這些設施在開業初期表現非常好,且優於我們的預期。因此我們對全年預期做了些微調整;考量到第二季末新增兩家新設施,以及第三季還會再開一家設施,我們會引導大家預期第三季該1,200萬美元的水準會略有上升。
So I think it could get a little bit larger, not significantly, but maybe in the $12 million to $14 million range before we really have an opportunity starting in the fourth quarter to see that number come back down certainly below the $12 million as we think about what's possible for the fourth quarter based on progress that we've made so far with those new facilities.
所以我認為金額可能會稍微變大一些,不會顯著,但可能落在1,200萬到1,400萬美元的區間;之後我們在第四季將有機會看到該數字回落,並且依據我們迄今在這些新設施上的進展,第四季確實有可能降到低於1,200萬美元。
Debra Osteen - Chief Executive Officer, Director
Debra Osteen - Chief Executive Officer, Director
And I'll just add, as you look at the facilities that we have, and certainly, we have our cohort group, but we also have same facility that we've had for some number of years, when they become 75% or higher in occupancy, they really are at a point where they have to start turning away patients due to age and sex and male, female to kind of programs. So we are looking at those facilities, and we believe that we have potential to add additional beds. And that's really the best return on our capital. And so we have a focus on that. In fact, we had a meeting earlier this week to look at what's out there, where our facility is at and how many of them can we start to really do our due diligence around whether bed additions are needed.
我再補充一下,當你看我們的設施時,當然我們有一個同批次(cohort)群組,但我們也有一些已營運多年的既有設施;當它們的入住率達到75%或更高時,基本上就會到達必須開始因年齡、性別(男性、女性)以及不同方案配置等因素而婉拒病患的程度。因此我們正在檢視這些設施,並相信我們有潛力再增加額外床位。而這其實是我們資本報酬率最好的做法。所以我們也把重點放在這裡。事實上,我們本週稍早才開會檢視外部情況、我們各設施目前的狀態,以及其中有多少家可以開始進行盡職調查(due diligence),評估是否需要新增床位。
Operator
Operator
Whit Mayo, Leerink Partners.
Whit Mayo,Leerink Partners。
Whit Mayo - Analyst
Whit Mayo - Analyst
To come back to the MedNow PLGL stuff for a minute. I mean, you knew a lot about the cases that you referenced. Has the frequency of claims changed or the settlement per claim change? Or is this all just new information on the movement in current legal proceedings. And just to be clear, is this viewed as onetime and not having an impact on forward reserves? And lastly, just how we get comfortable that there won't be additional actuarial reserves that you have to take?
我想再回到MedNow PLGL的議題一下。我的意思是,你對你提到的那些案件了解很多。索賠的頻率有改變嗎?或是每件索賠的和解金額有改變嗎?還是這些都只是目前法律程序進展所帶來的新資訊?另外確認一下,這是否被視為一次性(onetime),且不會影響未來的準備金(reserves)?最後,你們如何能讓我們放心,不會還需要再提列額外的精算準備金?
David Duckworth - Interim Chief Financial Officer
David Duckworth - Interim Chief Financial Officer
Yes. Well, thanks for your question. We did plan just moving into 2026 to conduct a midyear review in addition to our fourth quarter review that we traditionally done. And I'd point you back to last year's actuarial adjustment, it was somewhat broad and the company talked about frequency of claims. And as we went through the update process with our actuary in the second quarter, we did see just for some of those 2025 claims that the company talked about last year that had a higher frequency, where we have seen the team be able to successfully move towards settlement just in a real intentional and proactive way of managing through some of those cases.
是的。謝謝你的提問。我們確實規劃在邁入2026年時,除了傳統上在第四季進行的檢視之外,還會在年中再做一次檢視。我也想請你回顧去年的精算調整,當時範圍相對較廣,公司也談到索賠頻率。而在第二季與我們的精算師進行更新流程時,我們確實看到,針對公司去年提到、在2025年索賠中頻率較高的部分案件,我們的團隊以非常有意識且主動的方式管理這些案件,並成功推進至和解。
We saw an adjustment of $28.6 million related specifically to some of those 2025 claims. And so would attribute this year's adjustment to just the higher case severity, certainly something that we believe is consistent with the litigation environment, the industry trend that many others in health care are seeing, but was specifically related from our perspective to the 2025 cases that we highlighted.
我們看到一項2,860萬美元的調整,係專門與其中部分2025年索賠相關。因此,我們會將今年的調整歸因於個案嚴重度(case severity)較高;這當然是我們認為與訴訟環境一致的現象,也是許多其他醫療保健業者所見到的產業趨勢,但就我們的角度而言,這項調整具體是與我們先前強調的2025年案件相關。
In terms of thinking about that as onetime or making a prediction as to going forward, are we going to see this again? That is very difficult to predict. We do a tremendous job as a team from my perspective, just on our risk management programs, controlling what we can control and focusing on safety, reducing events and negative outcomes. And this involves technology. This involves people, processes at our facility.
至於把這視為一次性,或要預測未來是否還會再發生——我們是否會再次看到這種情況——這非常難以預測。我們團隊在我看來,在風險管理計畫上做得非常出色,盡力控制我們能控制的部分,並聚焦於安全、降低事件發生與不良結果。這涵蓋科技。也涵蓋人員。以及我們各設施內的流程。
So there continues to be a tremendous focus on that as well as our approach for defending and managing claims, which is customized for each case that we have, that we are working to resolve in a strategic and an aggressive way to defend those cases that we do have for previous years.
因此,除了上述重點之外,我們在抗辯與管理索賠的方式上也持續高度聚焦;我們對每一個案件都採取客製化策略,並以策略性且積極的方式推動解決,同時也積極為我們過往年度的案件進行抗辯與管理。
I will highlight for the current year, our recent actuarial report did not change the forecast that we had for 2026 from the previous year's actuarial report. We've talked with investors about seeing POGO step up over the last several years and having a range of expected costs for 2026 of $100 million to $110 million. Our midyear review continues to have that expectation for the current year. But as we think about adding the prior year adjustment to that, the current year will now be trending in more of a $135 million range, but continue to see and be encouraged by the current year being in line with our expectations.
我想強調,就本年度而言,我們最新的精算報告並未改變相較於前一年度精算報告中對2026年的預測。我們也曾與投資人談到,過去幾年POGO呈現上升趨勢,並且對2026年的預期成本區間為1億到1.1億美元。我們的年中檢視仍維持對本年度的這項預期。但若把前一年度的調整加進來,本年度目前的趨勢將更接近1.35億美元左右;不過我們仍看到、也受到鼓舞的是,本年度本身仍符合我們的預期。
Whit Mayo - Analyst
Whit Mayo - Analyst
Okay. And then my follow-up, just on Medicaid work requirements. A lot of this is very confusing to me. I don't understand the definition of a lot of stuff around the definition of treatment and disabling. Just wanted to get any updated views you think that you may have.
好的。那我追問一下,關於Medicaid的工作要求。這裡面很多內容對我來說很混亂。我不太理解很多定義,例如治療(treatment)與失能(disabling)的定義。想請教你是否有任何更新的看法。
Debra Osteen - Chief Executive Officer, Director
Debra Osteen - Chief Executive Officer, Director
Yes. As we think about the work requirements, I'm sure you know that it doesn't impact all of the states, that's kind of the first point here. As they implement this in January, it will be for those that have expanded Medicaid. And what I think the association in ABH, which is our association and just various groups have done is really show that our patients need to have some provision for these work requirements. And I think that as we look at it and how it will impact Acadia, we don't believe that there will be a material impact.
是的。談到工作要求時,我相信你也知道,它並不影響所有州,這是第一點。當各州在一月開始實施時,將適用於那些已擴大Medicaid的州。而我認為,ABH的協會(也就是我們的協會)以及各類團體所做的,是清楚表明我們的病患需要在這些工作要求上有某些配套條款。就我們的觀察以及它對Acadia的影響而言,我們不認為會造成重大影響。
We think our patients will qualify for the exemptions that have been laid out. I think they've been very thoughtful about how they've done that and with respect to severe mental illness as well as substance use. And there are provisions in there. We feel like they will cover our patients. And so we work in collaboration just trying to lay out how the difference between the behavioral health and substance use patient and a med-surg patients.
我們認為我們的病患將符合已制定的豁免條件。我認為他們在制定方式上非常周全,並且也涵蓋嚴重精神疾病以及物質使用。而且其中也有相關條款。我們覺得這些將能涵蓋我們的病患。因此我們以合作方式運作,試著釐清行為健康與物質使用病患,與內外科(med-surg)病患之間的差異。
Operator
Operator
Pito Chickering, Deutsche Bank.
Pito Chickering,德意志銀行。
Pito Chickering - Research Analyst
Pito Chickering - Research Analyst
I guess the first question, can you talk about the revenue growth within the CDC clinics. I think it's sort of down just a smidgen year-over-year just by adding six more centers. I guess how is the mix methadone market? How is sort of the macro demand there? And how should we think about 2Q results of decelerating trends? And what do you see in the guidance for the rest of the year?
我想第一個問題是,能否談談 CDC 診所的營收成長。我認為在新增六個中心之後,年對年看起來只是小幅下滑一點點。我想問一下美沙冬(methadone)市場的組合如何?那邊的總體需求情況如何?以及我們應該如何看待第二季(2Q)結果中趨勢放緩?另外,對於今年剩餘期間的指引,你們看到了什麼?
David Duckworth - Interim Chief Financial Officer
David Duckworth - Interim Chief Financial Officer
Yes. Pito, we mentioned earlier, we are pleased with just the demand, the opportunity that we continue to see and the team that we have leading the CDC service line. It did perform slightly behind our expectations for the second quarter, and was flat on a year-over-year basis from a revenue perspective. We have seen growth in the number of clinics in that market and continue to see some opportunities in other markets to continue to add clinics selectively and based on where we now see some opportunity and ability to think about capital investments and growth in that space.
好的。Pito,我們先前提到過,我們對於持續看到的需求與機會,以及帶領 CDC 服務線的團隊感到滿意。第二季的表現略低於我們的預期,從營收角度來看年對年持平。我們看到該市場的診所數量在成長,也持續在其他市場看到一些機會,能夠有選擇性地新增診所,並依據我們目前看到的機會與在該領域進行資本投資與成長的能力來推進。
But we do see an opportunity there, given some of the slight underperformance in the second quarter, but with the strong demand capacity and team that we have and demand that we still see in that service line, we do see continued opportunity there to improve the revenue growth and the performance of that business.
不過,鑑於第二季些微低於預期的表現,但我們擁有強勁的需求承載能力與團隊,且在該服務線仍看到需求,我們確實認為仍有持續機會去改善營收成長與該業務的表現。
Debra Osteen - Chief Executive Officer, Director
Debra Osteen - Chief Executive Officer, Director
And I'll just add, 25% of Americans received treatment, which leaves a very large group of individuals in the country that do not see care. And the incidence of opioid use remains high. And I think that there's -- as David said, we see continued demand. What we want to do is make sure that our clinics are the first choice. And so we're looking at all aspects of that business to make sure that our services and just the patient -- client experience is positive and other things with respect to just how we might deploy our marketing dollars. So it's an area that we still feel very positive about and demand remains strong. But we want to make sure that all of our clinics are first choice in all the regions that we're in.
我再補充一下,只有 25% 的美國人接受了治療,這表示國內仍有非常龐大的一群人沒有獲得照護。而且阿片類藥物使用的發生率仍然很高。我認為——如 David 所說,我們看到需求持續存在。我們想做的是確保我們的診所成為首選。因此我們正在檢視這項業務的各個面向,確保我們的服務以及病患/客戶體驗是正向的,並且也在思考行銷預算的投放方式等事項。所以這仍是我們非常看好的領域,需求依然強勁。但我們要確保在我們所在的所有區域,我們的所有診所都是首選。
Pito Chickering - Research Analyst
Pito Chickering - Research Analyst
Okay. And then a follow-up here. Debbie, you brought in turn the company around second time. Can you give color on the initiations you put in place in its second quarter as it relates specifically to corporate changes and why the de novos are having better in '26 than they were in '25?
了解。接著一個追問。Debbie,你第二次把公司帶回正軌。能否提供一些背景,說明你在第二季所推動的措施,特別是與公司層級變革相關的部分,以及為什麼新設據點(de novos)在 2026 年的表現比 2025 年更好?
Debra Osteen - Chief Executive Officer, Director
Debra Osteen - Chief Executive Officer, Director
Well, I think I've said in previous calls that to be the people, one of the most important things that we have. They have to -- we have to have the right experienced people. So I've given a lot of focus to just reviewing our talent across not just at the corporate level, but at the facility level as well. And we made some changes around how we are organized within the operational structure, particularly in the acute service line.
我想我在先前的電話會議中說過,人——也就是我們的員工——是我們最重要的資產之一。他們必須——我們必須擁有合適且有經驗的人才。因此我投入了很多心力,檢視我們的人才配置,不僅在公司層級,也包括各個機構層級。我們也針對營運架構中的組織方式做了一些調整,特別是在急性照護服務線。
We restructured that really to flatten some of the structure and to think about geography and think about SCO as the leaders in the queue, assist the facilities and assist the CEO. So that's been a key focus. And I think everyone -- I think it's working. And as I said in my remarks, I think we're seeing the benefit of that.
我們重新調整架構,主要是讓層級更扁平,並從地理區域的角度思考,讓 SCO 作為前線領導者,協助各機構並協助 CEO。這一直是我們的重點。我想大家——我認為這正在發揮作用。而且如我在致詞中所說,我認為我們正在看到其效益。
We did -- at the corporate level, we did take out a level of middle management just to facilitate problem-solving to assist the facilities. We looked at what is the sense for them to have and support. We also, with respect to just the cohorts, they're not just JV partners, as you mentioned, they're de novos as well. But we have improved our alignment and communication. Part of that was bringing in management to focus on the JVs. I think there are best practices that can be really deployed across our company with respect, even though they're all very different.
在公司層級,我們確實精簡了一層中階管理,以促進問題解決並協助各機構。我們檢視了他們應該具備並提供哪些支援才合理。另外,就這些群組(cohorts)而言,如你提到的,他們不只是合資(JV)夥伴,也包括新設據點(de novos)。但我們已改善了彼此的對齊與溝通。其中一部分是引進管理人員來專注於合資案(JVs)。我認為即使各案差異很大,仍有一些最佳實務可以在公司內部更廣泛地推行。
So as we have looked at those cohorts, we've been able -- as we looked at the process last year that was difficult and in some cases, took longer than was expected, we've been able to cut the time in half for those approvals. And I think that's really just a matter of focus. We are working with our partners, we're leveraging them, and we're moving faster to those approvals so that then we can begin ramping and taking patients with respect to Medicare and Medicaid, but also just accelerating our payer contracting and other pieces that have to work together to see those facilities ramp. And our goal is to ramp faster, and we are pleased with what we see in the second quarter.
因此,當我們檢視這些群組時——回顧去年那段艱難、且在某些情況下耗時比預期更久的流程——我們已能把那些核准所需時間縮短一半。我認為這真的就是專注度的問題。我們正與合作夥伴一起工作、善用他們的資源,並加速取得核准,這樣我們就能開始爬坡(ramping)並收治病患,包含 Medicare 與 Medicaid,同時也加速保險支付方合約(payer contracting)以及其他必須協同運作的環節,讓這些機構能順利爬坡。我們的目標是更快爬坡,而我們對第二季看到的情況感到滿意。
Operator
Operator
Ryan Langston, TD Cowen.
Ryan Langston,TD Cowen。
Ryan Langston - Analyst
Ryan Langston - Analyst
Government investigation costs continue to decline, should we read anything into that in terms of settling some of the outstanding issues you're dealing with there? Or is this maybe more just a good run rate expense we should be thinking about modeling in the near term?
政府調查相關成本持續下降,我們是否可以從中解讀為你們正在就一些尚未解決的問題達成和解?還是說,這比較只是我們在短期內建模時應視為一個較好的常態化費用水準(run rate expense)?
David Duckworth - Interim Chief Financial Officer
David Duckworth - Interim Chief Financial Officer
We -- it's difficult to provide any sort of outlook on those costs. Yes, it was lower in the quarter, certainly lower than what we incurred in the second quarter of last year. But expense going forward will just be a function of the next steps in that process. We're cooperating fully and heavily focused on the process and wouldn't make a prediction at this point in time as to where those costs will be in the second half of the year going forward.
我們——很難就這些成本提供任何形式的展望。是的,本季確實較低,當然也低於去年第二季我們所發生的金額。但未來的費用將取決於該流程下一步的進展。我們正全力配合並高度專注於該流程,目前不會對今年下半年及往後這些成本會落在何處做出預測。
Ryan Langston - Analyst
Ryan Langston - Analyst
Okay. And then obviously, over the last few quarters, you've highlighted some friction with your payer partners. Maybe just give us a sense sort of where you're at in those payer relationships? And if you've been able to make any progress on improving those relationships in general and maybe settling any particular disagreements we've had over maybe the last year or so?
了解。另外,顯然在過去幾個季度,你們提到與保險支付方夥伴之間存在一些摩擦。能否請你們說明一下目前與這些支付方的關係進展到哪個程度?以及你們是否已在整體上改善這些關係方面取得任何進展,並且可能解決過去一年左右出現的一些特定分歧?
Debra Osteen - Chief Executive Officer, Director
Debra Osteen - Chief Executive Officer, Director
Well, I think I've said before that there's always the push and pull that we have. And over my career in behavioral health, there's always that push and pull. So as far as our relationships with payers, I think that they are strong. I think that they want to ensure that their patients get the right care. We want that too.
我想我之前說過,我們之間一直都會有拉鋸。而在我整個行為健康領域的職涯中,一直都有這種拉鋸。就我們與支付方的關係而言,我認為是穩固的。我認為他們希望確保他們的病患獲得正確的照護。我們也希望如此。
We advocate for our patients and we make sure that we're able to document acuity. And so as we -- I think about just where we sit today, I think that we have good relationships really in many of our markets, we -- it's really specific, I think, to certain geographies. Sometimes you find a payer that might be more aggressive than others. We are prepared to step up and make sure we're doing our job, make sure we're giving them what they need with documentation.
我們為病患發聲,並確保我們能夠記錄病情嚴重度(acuity)。因此,當我們——我思考我們今天所處的位置時,我認為我們在許多市場確實都建立了良好的關係;我們——我認為這在某些特定地理區域上更為明顯。有時你會遇到某些付款方(payer)比其他人更具進取性。我們已準備好挺身而出,確保我們把工作做好,確保我們用文件紀錄提供他們所需要的內容。
We also -- we've been receiving rate increases from our payers low to single mid-single digits. But on the other hand, we also now have outcomes which we're sharing with our payers. And I think that my view on payers is we need to be collaborative. And we need -- and in many cases, I can think of several, they've asked us to do certain services. And so we want to work with them.
另外——我們一直從付款方那裡獲得費率調升,幅度約為低個位數到中個位數的低端。但另一方面,我們現在也有治療結果(outcomes),並與付款方分享。我對付款方的看法是,我們需要以合作的方式來互動。而且我們需要——在許多情況下,我可以想到好幾個例子,他們要求我們提供某些服務。因此我們希望與他們合作。
But they're still going to be that tension and I've seen it over many years, but it's still -- they respect our clinical expertise. And I think that what we want to do is make sure that we're doing our job with providing clinical excellence, and we have to demonstrate that to them. And I think that, that's always going to be there, this kind of tension that happens between us and restricting care. Our job is to make sure that our patients get the right care in the right setting at the right time. And so that's what we're focused on.
但這種緊張關係仍然會存在,我多年來都看過;不過他們仍然——尊重我們的臨床專業。我認為我們想做的是,確保我們在提供卓越臨床照護方面把工作做好,而且我們必須向他們證明這一點。我認為這種——我們與限制照護之間所產生的緊張關係,永遠都會存在。我們的工作是確保病患在正確的時間、於正確的場域,獲得正確的照護。因此這就是我們專注的重點。
Operator
Operator
Ann Hynes, Mizuho Securities.
Ann Hynes,瑞穗證券(Mizuho Securities)。
Ann Hynes - Analyst
Ann Hynes - Analyst
So your same-store emission growth was very strong at over 6%, but your revenue same-store growth adjusted for the DPP was only 3.2%. And I would think those should kind of align. So maybe can you tell us like why the revenue grew under a mission. And then maybe -- I don't know if you've ever done this, but can you breakout emission by your service line and how that trended through the quarter?
所以你們同店(same-store)收治/入院(admission)成長非常強勁,超過6%,但你們在扣除DPP調整後的同店營收成長只有3.2%。我原本以為這兩者應該大致一致。所以也許你能告訴我們,為什麼營收成長低於收治/入院成長。然後也許——我不知道你們是否做過,但你們能否按服務線(service line)拆分收治/入院,並說明其在本季的趨勢?
David Duckworth - Interim Chief Financial Officer
David Duckworth - Interim Chief Financial Officer
Yes. And we would just highlight the service mix changes that we've talked about with bed additions being heavily weighted on the acute side. So what we're seeing and we'll continue to see is just a stable mix within the service lines as we look at metrics on admissions and patient days, but with the heavier mix of acute within our bed count and within our business. The acute admissions are at a much higher level, just given the longer stay associated with RTC and specialty. And so it's just -- it's a mix item.
可以。我們會強調我們先前談到的服務組合(service mix)變化:新增床位(bed additions)在急性端(acute side)的比重很高。因此我們看到、且將持續看到的是:當我們觀察入院數與病患日(patient days)等指標時,各服務線內部的組合大致穩定,但在我們的床位數與業務中,急性照護的占比更高。由於RTC與專科(specialty)相關的住院天數較長,急性入院(acute admissions)處於更高水準。所以這——主要是組合因素(mix item)。
We were pleased with the performance of the individual service lines, but acute being a heavier mix of the company, both this quarter and even continuing moving forward, we are going to continue to see that dynamic.
我們對各個服務線的表現感到滿意,但由於急性照護在公司中的占比更高——無論是本季,甚至展望未來——我們將持續看到這種動態。
Ann Hynes - Analyst
Ann Hynes - Analyst
Great. And I know some of the payers are pushing from more outpatient intensive care rather than inpatient admit, is that trend still continuing? Can you remind us what your exposure is to outpatient intensive?
很好。我知道有些付款方正推動更多門診密集照護(outpatient intensive care),而不是住院收治(inpatient admit);這個趨勢還在持續嗎?你能提醒我們,你們在門診密集照護方面的曝險/比重(exposure)是多少嗎?
Debra Osteen - Chief Executive Officer, Director
Debra Osteen - Chief Executive Officer, Director
Well, we want our patients to get the right care. And so if they do meet inpatient criteria medical necessity, and that's where they need to be. However, we believe fully in the continuum. And so I think you used the word push. I think what we want to do is make sure that they're getting the right level of care. So we have, in many of our hospitals step down in either IOP, which is intensive outpatient and partial which is partial hospital.
嗯,我們希望病患能獲得正確的照護。因此,如果他們符合住院標準與醫療必要性(medical necessity),那他們就應該在住院端接受照護。不過,我們完全相信照護連續體(continuum)。所以我想你用了「推動」這個詞。我認為我們想做的是確保他們獲得正確層級的照護。因此在我們許多醫院,我們在出院後的銜接上提供IOP(密集門診,intensive outpatient)以及partial(部分住院/日間住院,partial hospital)。
So as we look at that, we see that as a natural part of where a patient after they get stabilized, then they would go to outpatient. And I think that we want to make sure that we have those resources available. We have continued to grow that line, and we're going to seek to look at that in total to see if there are other opportunities, but we're very much a believer that a patient needs to be in the right setting. So if outpatient is appropriate and they're ready for that, then we support that fully.
因此當我們看待這一點時,我們認為這是病患在病情穩定後,轉往門診的自然流程。我認為我們希望確保這些資源可供使用。我們持續擴展這條業務線,並且會從整體角度檢視,看看是否還有其他機會;但我們非常相信,病患需要在正確的場域接受照護。所以如果門診是合適的,而且他們已準備好,那我們完全支持。
Operator
Operator
Due to time constraints, this concludes our question-and-answer session. I'd like to turn the conference back over to Debbie Osteen for any closing remarks.
由於時間限制,我們的問答環節到此結束。我想把電話會議交回給Debbie Osteen,請她做任何結語。
Debra Osteen - Chief Executive Officer, Director
Debra Osteen - Chief Executive Officer, Director
I want to thank you for your time this morning and for your interest in Acadia Healthcare. Please feel free to contact us if you have any additional questions. Have a good day.
感謝各位今天早上的時間,以及對Acadia Healthcare的關注。如果您還有任何其他問題,歡迎隨時與我們聯繫。祝您有美好的一天。
Operator
Operator
Conference has now concluded. Thank you for attending today's presentation. You may now disconnect.
本次電話會議已結束。感謝您參加今天的簡報。您現在可以斷線。